未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
Mandal, Tirtha; Gnanasegaran, Soorya; Rodrigues, Golding; Kashipathi, Shalini; Tiwari, Anurag; Dubey, Ashvini Kumar; Bhattacharjee, Sanghamitra; Manjunath, Yogendra; Krishna, Subith; Madhusudhan, M. S.; Ghosh, Maloy
分享
收藏
分享
收藏
分享
收藏Phase 1 clinical trial of the anti-LLT1 antibody ZM008 as monotherapy and in combination with pembrolizumab in advanced solid tumor patients
Ghosh, M.; Garcia Ribas, I.; Fuloria, J.; Rivera, I. Rodriguez; Vandross, A.; Tiwari, A.; Dubey, A. K.; Bhattacharjee, S.; Manjunath, Y.; Kashipathi, S.; Mandal, T.
分享
收藏
分享
收藏
分享
收藏
分享
收藏First-in-human phase 1 clinical trial of ZM008, a monoclonal IgG1 targeting LLT1, monotherapy and in combination with pembrolizumab in advanced solid tumors
Ghosh, Maloy; Tiwari, Anurag; Dubey, Ashvini Kumar; Bhattacharjee, Sanghamitra; Manjunath, Yogendra; Kashipathi, Shalini; Krishna, Subith; Mandal, Tirtha; Madhusudhan, M. S.; Rodrigues, Golding
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Madhusudhan, M. S.; Garcia Ribas, I.; Ghosh, M.; Tiwari, A.; Dubey, A.; Bhattacharjee, S.; Manjunath, Y.; Kashipathi, S.; Krishna, S.; Mandal, T.; Gnanasegaran, S.; Rodrigues, G.
分享
收藏